Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ocular diseases
Biotech
Aldeyra forewarns potential FDA rejection for dry eye med
Aldyera's shares fell more than 60% after the biotech indicated the FDA could soon reject its dry eye disease med due to a lack of convincing data.
Max Bayer
Oct 16, 2023 2:49pm
Editas shelves lead asset after disappointing phase 1/2 data
Nov 17, 2022 10:22am
Intellia expands ocular pipeline with 10% stake in SparingVision
Oct 13, 2021 7:00am
Visus, with one drug chasing AbbVie, inks deals to grow pipeline
Aug 19, 2021 8:35am
Immunocore gets FDA breakthrough nod for eye melanoma drug
Feb 19, 2021 8:45am
Psychedelics relieve asthma in rats with no mental effects
Aug 13, 2020 8:00am